K

Korsana Biosciences

Develops THETA-enabled neurodegenerative therapeutics

Senior Director - Biologics Drug Substance Development and Manufacturing

Bioprocess & BiomanufacturingUpdated on Nov 15
Full-timeBoston, MA, USAIn-person

About the Job

Requirements

  • A Ph.D. in biochemistry, biochemical engineering, or another relevant physical or life sciences discipline, or an MS/BS with equivalent education or experience, is required.
  • A minimum of 12 years of hands-on experience in biologics drug substance development in the biotech or biopharma industry is required.
  • Demonstrated ability to lead and manage biologics drug substance manufacturing process development, optimization, characterization, scale-up, and GMP manufacturing in an outsourced business model.
  • A proven track record of CDMO selection and management in support of biologics drug substance development and GMP manufacturing is required.
  • Hands-on experience with global CMC regulatory submission and approval is required.
  • The candidate must be able to balance long-term planning with day-to-day execution, influence across levels and functions, solve problems with attention to detail, and distinguish critical from non-critical priorities.

Responsibilities

  • Provide program-specific leadership and subject matter expertise for drug substance development and manufacturing activities supporting preclinical and clinical programs.
  • Oversee planning and execution of outsourced drug substance development and manufacturing; work with external suppliers, including CDMOs and contract labs, to define project scope, mitigate risks, and deliver against technical quality, timelines, and budget.
  • Collaborate with other functions to deliver quality products for preclinical studies and clinical trials and Module 3 Quality for regulatory submission and approval.
  • Establish effective CMC strategies for biologics drug substance manufacturing process development, optimization, characterization, scale-up, and GMP manufacturing across a portfolio of biologics, aligned with corporate and program objectives.
  • Collaborate with internal stakeholders in Drug Product Development, Combination Product Development, Analytical Development and Quality Control, Clinical Supply Chain, Program Management, Preclinical Development, Clinical Development/Operations, Quality, and Regulatory Affairs, as well as external business partners, to advance projects.
  • Create metrics for the drug substance function, monitor results, and implement risk-management strategies to address technical challenges and meet business goals.
  • Partner with QA to support deviation and OOS investigations and associated CAPAs for drug substance release and stability testing.
  • Prepare CMC documentation for regulatory and/or patent filings.
  • Lead CDMO/CRO selection, contract negotiation, and budget and scope management related to drug substance development and manufacturing.
  • Maintain an understanding of current trends and emerging biologics drug substance manufacturing technologies.
  • Communicate progress against technical objectives and milestones to management.
  • Ensure clear, complete, and well-organized records of activities across areas of responsibility.

Desired Qualifications

  • Experience in a fast-paced, high-growth startup environment is preferred.
  • Experience in successful IND/IMPD is preferred.

About the Company

Korsana Biosciences

Develops THETA-enabled neurodegenerative therapeutics

Korsana Biosciences develops therapies for neurodegenerative diseases, with a focus on Alzheimer's disease. Its lead candidate KRSA-028 is a monoclonal antibody that targets amyloid beta and uses the THETA platform to shuttle across the blood-brain barrier, increasing brain exposure. THETA combines TfR1-based shuttling and Fc engineering to improve brain delivery and enable subcutaneous administration while aiming to reduce ARIA risks. The company plans to advance THETA-enabled therapies through clinical trials, with safety data expected in 2027 and initial amyloid clearance proof-of-concept by the end of 2027, supported by funding into 2028.

Company size
11-50
Company stage
IPO
Headquarters
Waltham, MA
Founded
2024

Recently Posted Jobs

Explore more opportunities at Korsana Biosciences

See more jobs